Replies to post #18638 on Oncolix Inc. (fka ONCX)

[reaper247]

LOL, lararz…lets look at facts.

Where is Oncolix since?
New Shell symbol?

Wrong, ONCX is not a shell.

billions more shares?

Wrong, the O/S is relatively unchanged @ roughly 110,000,000.

90% stock loss?

Wrong, the PPS is still trading higher than AEPP lows prior to the R/M.

Toxic Debt?

Notes have been renegotiated with equity and interest accrued until Q2 2019.

Millions of dollars in Interest payments?

Wrong. A relatively small note of $5.4 accrues interest @ a 10% annum with equity and interest accrued until Q2 2019

No Revenue?

That is a given with a pre-revenue bio/pharma company engaged in FDA clinical trials.

No word of any recruits?

Wrong. Results from the original cohort are in ONCX SEC filings and ONCX investor presentations. There are also ONCX CEO interviews available that cover this.

No word on who is producing Prolanta?

BioVectra (a subsidiary of Mallinckrodt PLC NYSE: MNK,) has been producing Prolanta and the former Biovectra CEO is an ONCX board member.

Huge compensation to Execs?

Wrong, the majority of compensation due to ONCX officers (roughly $1,200,000) has been deferred.

Inventor of Prolanta leaving company?

Wrong. The inventor of Prolanta, Dr. Chen was never an ONCX employee.

shareholders wishing ONCX would go back to AEPP?

LOL, not likely.

IMO and FWIW.